NCT01331915Unknown1 期
Phase I/II Study of Therapeutic Vaccination With Escalating Doses of Theravac®, a Proteinic Vector Targeting Dendritic Cells Coupled to a Melanoma Antigen, in Patients With Advanced Metastatic Melanoma.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain2 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2010年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- To analyze the safety and toxicity of increasing doses of Theravac® in patients with advanced metastatic melanoma
研究概览
简要总结
In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease.
The primary objective is to analyze the safety of the inreasing doses of vaccine.
The secondary objective is to document whether this vaccine can induce tumor regression in immunized patients.
详细描述
There are three treatment cohorts and the inclusion of patients in governed by the dose-limiting toxicities in the previous cohort.
- the first three patients will receive a dose of 50 µg of Theravac®
- second cohort of three patients will receive a dose of 150 µg Theravac®
- the third cohort of three patients will receive a dose of 250 µg Theravac® and eventually a total of 14 patients will complete the step with the highest dose.
All the patients will receive four immunizations every three weeks in two intradermal sites and in two subcutaneous sites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven cutaneous, uveal or mucosal melanoma.
- •Melanoma must be metastatic. The origin of the primary could be cutaneous, uveal or mucosal and any metastatic stage is accepted, except if brain or leptomeningeal localizations are present, or if plasma LDH are elevated more than 1.5 normal upper values (see also below).
- •HLA-A2 positive.
- •The melanoma must express the tyrosinase gene (positive RT-PCR on a frozen pre-immune tumor sample) (see Appendix B).
- •At least one measurable or non-measurable tumor lesion (see Section 8.1).
- •Expected survival of at least 3 months.
- •Karnofsky performance scale ≥70 or WHO performance status of 0 or 1 (see Appendix C).
- •Vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:
- •Lab Parameter Range Hemoglobin ≥ 10 g/dl or ≥ 6,25 mmol/l Granulocytes ≥ 1,500/µl Lymphocytes ≥ 700/µl Platelets ≥ 100,000/µl Serum creatinin ≤ 2.0 mg/dl or ≤ 177 μmol/l Serum bilirubin ≤ 2.0 mg/dl or ≤ 34.2 μmol/l ASAT and ALAT ≤ 2 x the normal upper limits LDH ≤ 1.5 x the normal upper limit.
- •Viral serology:
- •HIV (human immunodeficiency virus): negative antibodies.
- •HBV (hepatitis B virus): negative antigens; antibodies may be positive.
- •HCV (hepatitis C virus): negative antibodies.
- •Age ≥ 18 years
- •Able and willing to give valid written informed consent
排除标准
- •Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).
- •Previous treatment with a vaccine known or likely to contain the Tyrosinase.A2 epitope YMDGTMSQV.
- •Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.
- •Active immunodeficiency or autoimmune disease. Vitiligo is not an exclusion criterion.
- •Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.
- •Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.
- •Allergy to kanamycin (used in the preparation of the recombinant protein) or to any other aminoglycoside antibiotic.
- •Lack of availability for immunological and clinical follow-up assessments.
- •Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
- •Pregnancy or breastfeeding.
- •Women of childbearing potential: Refusal or inability to use effective means of contraception.
结局指标
主要结局
To analyze the safety and toxicity of increasing doses of Theravac® in patients with advanced metastatic melanoma
时间窗: the first 3 months of treatment
The toxicity will be assess after the treatment (3 months) for the first three patients of each group.
To determine whether these immunizations result in a detectable immune response
时间窗: Up to 24 weeks
PBMC will be obtained from the buffy-coat of 500 ml of venous blood or from 100 ml of venous blood collected before and after immunization.
次要结局
- To document whether this vaccine can induce tumor regression in immunized patients.(at week 12)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)Cancer.Melanoma.Ovarian Cancer.Lung Cancer.NCT01584115Instituto de Investigação em Imunologia15
已完成
2 期
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell CancerCarcinoma, Renal CellNCT00083941Oxford BioMedica25
已完成
1 期
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by SurgeryMetastatic Malignant Peripheral Nerve Sheath TumorNeurofibromatosis Type 1Recurrent Malignant Peripheral Nerve Sheath TumorNCT02700230Mayo Clinic30
已完成
1 期
A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine CandidateChronic Hepatitis BNCT05727267Universitätsklinikum Hamburg-Eppendorf26
进行中（未招募）
1 期
Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanomaEUCTR2008-006253-41-NOThe Norwegian Radium Hospital, Oslo University Hospital25